BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32522823)

  • 1. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
    Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
    Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
    Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
    Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
    Guo Y; Wang J; Benedict B; Yang C; van Gemert F; Ma X; Gao D; Wang H; Zhang S; Lieftink C; Beijersbergen RL; Te Riele H; Qiao X; Gao Q; Sun C; Qin W; Bernards R; Wang C
    Genome Med; 2021 Oct; 13(1):166. PubMed ID: 34663432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells.
    Rogers RF; Walton MI; Cherry DL; Collins I; Clarke PA; Garrett MD; Workman P
    Cancer Res; 2020 Apr; 80(8):1735-1747. PubMed ID: 32161100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
    Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
    Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
    Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
    Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A.
    Shen S; Yue H; Li Y; Qin J; Li K; Liu Y; Wang J
    Tumour Biol; 2014 Jan; 35(1):631-40. PubMed ID: 23959478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
    Ro EJ; Ryu SH; Park EY; Ryu JW; Byun SJ; Heo SH; Kim KH; Baek IJ; Son BH; Lee SW
    Breast Cancer Res Treat; 2020 Aug; 182(3):591-600. PubMed ID: 32529408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.
    Mohni KN; Kavanaugh GM; Cortez D
    Cancer Res; 2014 May; 74(10):2835-45. PubMed ID: 24662920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
    Kalev P; Simicek M; Vazquez I; Munck S; Chen L; Soin T; Danda N; Chen W; Sablina A
    Cancer Res; 2012 Dec; 72(24):6414-24. PubMed ID: 23087057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
    Lee HJ; Hwang HI; Jang YJ
    Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
    Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
    Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.